Skip to main content

Adage Capital Management — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

76
Companies
$11.1B
Total invested
$160.5M
Avg. check
22
Industries
Biotechnology 22Therapeutics 11Health Care 11Pharmaceutical 7Medical 7Life Science 5+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 76
Kailera Therapeutics
October 2025

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

Biotechnology · Waltham$600.0M Series B
Spyre Therapeutics
October 2025

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

Biotechnology · Sunrise$275.0M Post Ipo Equity
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post Ipo Equity
Arvinas
August 2025

Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.

Biotechnology · New HavenPost Ipo Equity
SiMa.ai
August 2025

SiMa.ai is a developer of machine learning technology to deliver a software-centric platform.

AI Infrastructure · San Jose$85.0M Series C
Trevi Therapeutics
June 2025

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$115.1M Post Ipo Equity
Tectonic Therapeutic
February 2025

Tectonic Therapeutic is a biotechnology company which focuses on scientific research in biochemistry and molecular pharmacology.

Biotechnology · Watertown$185.0M Post Ipo Equity
Cullinan Therapeutics
April 2024

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Biopharma · Cambridge$280.0M Post Ipo Equity
Akero Therapeutics
March 2024

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Biotechnology · Cambridge$366.9M Post Ipo Equity
Applied Therapeutics
February 2024

Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.

Biotechnology · New York$100.0M Post Ipo Equity
Beckley Psytech
January 2024

Beckley Psytech is a biotechnology company developing psychedelic-based medicines for mental health conditions.

Biotechnology · Beckley$40.0M Undisclosed
Arcellx
November 2023

Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.

Biopharma · Redwood City$200.0M Post Ipo Equity
Cerevel Therapeutics
October 2023

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Biotechnology · Boston$450.0M Post Ipo Equity
Poseida Therapeutics
August 2023

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Biopharma · San Diego$50.0M Post Ipo Equity
connectRN
May 2023

ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support.

Health Care · Waltham$750K Convertible Note
MedAvail
March 2023

MedAvail focuses on the discovery, development, and commercialization of advanced nutrition products.

Biotechnology · Mississauga$16.0M Post Ipo Equity
Aptinyx
November 2022

Aptinyx Inc. is a biopharmaceutical company.

Biopharma · Evanston$5.6M Grant
Werewolf Therapeutics
May 2022

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Biotechnology · Cambridge$50.0M Post Ipo Secondary
Calithera Biosciences
March 2022

Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.

Biotechnology · South San Francisco$10.0M Post Ipo Equity
Puma Biotechnology
March 2022

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.

Biotechnology · Los Angeles$10.0M Post Ipo Equity
Pyramid Biosciences
October 2021

Pyramid Biosciences is a provider of biotechnological services.

Biotechnology · Needham$33.5M Series B
Theseus Pharmaceuticals
April 2021

Theseus Pharmaceuticals is a technology-based company.

Biotechnology · New York$100.0M Series B
Flame Biosciences
September 2020

Flame Biosciences is a clinical-stage company focused on therapies for cancer and other inflammatory diseases.

Biotechnology · New York$100.0M Series Unknown

Where Adage Capital Management invests

Biotechnology22
Therapeutics11
Health Care11
Pharmaceutical7
Medical7
Life Science5

About Adage Capital Management's portfolio

How many companies has Adage Capital Management invested in?

Adage Capital Management has invested in 76 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Adage Capital Management invest in?

Adage Capital Management's top investment sectors include Biotechnology, Therapeutics, Health Care, Pharmaceutical, Medical. The firm invests across 22 different industry categories.

What is Adage Capital Management's largest investment?

Among tracked funding rounds, Kailera Therapeutics received $600.0M in a Series B round. Adage Capital Management's total known invested capital is $11.1B.

What is the average investment size for Adage Capital Management?

Adage Capital Management's average investment size is $160.5M across its portfolio of 76 companies.

What are Adage Capital Management's most recent investments?

Recent Adage Capital Management portfolio additions include Kailera Therapeutics, Spyre Therapeutics, Cidara Therapeutics, Pepgen, Arvinas. These companies were founded in 2020 or later.

Reach the founders behind these 76 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →